CoChat

ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid‐β copathology

Open access
Koriath, Carolin, Lashley, Tammaryn, Taylor, William, Druyeh, Ronald, Dimitriadis, Athanasios, Denning, Nicola, Williams, Julie, Warren, Jason D., Fox, Nick C., Schott, Jonathan M., Rowe, James B., Collinge, John, Rohrer, Jonathan D., Mead, Simon · 2019 · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Cited by 45

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Introduction: Apolipoprotein E (ApoE) is the most important genetic risk factor for Alzheimer's disease (AD), with ApoE4 thought to enhance and accelerate amyloid‐β (Aβ) pathology. ApoE4 has recently been described to increase neurodegeneration in a mouse model of frontotemporal dementia (FTD), in vitro, and in patients, demonstrating that ApoE4 modifies tauopathy independently of Aβ. This raises the question whether ApoE genotype also modifies the clinical phenotype in patients with FTD with tau pathology. Methods: We analyzed 704 patients with FTD, including a genetically and neuropathologically confirmed subset, and 452 healthy elderly controls. We compared ApoE4 genotype frequency and age at onset in tau+ or TDP43+ FTD patients with or without Aβ copathology. Results: The ApoE4 genotype lowered age at onset in patients with FTD and tau pathology, particularly once accounting for confounding effects of Aβ pathology. Discussion: We conclude that ApoE4 accelerates neurodegeneration in FTD patients with MAPT mutations or FTLD‐tau pathology, independent of Aβ.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dadm.2019.01.010

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 45

Metadata

Authors
Koriath, C., Lashley, T., Taylor, W., Druyeh, R., Dimitriadis, A., Denning, N., Williams, J., Warren, J. D., Fox, N. C., Schott, J. M., Rowe, J. B., Collinge, J., Rohrer, J. D., & Mead, S.
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2019-03-19
Volume
11
Issue
1
Pages
277-280
ISSN
2352-8729 (ISSN-L)
OpenAlex
W2947911948
Cited by
45
References
6
FWCI
3.14
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid‐β copathology. https://app.cochat.ai/papers/10.1016/j.dadm.2019.01.010
The paper
Koriath, C., Lashley, T., Taylor, W., Druyeh, R., Dimitriadis, A., Denning, N., Williams, J., Warren, J. D., Fox, N. C., Schott, J. M., Rowe, J. B., Collinge, J., Rohrer, J. D., & Mead, S. (2019). ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid‐β copathology. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2019.01.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.